Frontotemporal dementia (FTD) encompasses a collection of clinically and pathologically diverse neurological disorders. Clinical features of behavioural and language dysfunction are associated with neurodegeneration, predominantly of frontal and temporal cortices. Over the past decade, there have been significant advances in the understanding of the genetic aetiology and neuropathology of FTD which have led to the creation of various disease models to investigate the molecular pathways that contribute to disease pathogenesis. The generation of in vivo models of FTD involves either targeting genes with known disease-causative mutations such as GRN and C9orf72 or genes encoding proteins that form the inclusions that characterize the disease pathologically, such as TDP-43 and FUS. This review provides a comprehensive summary of the different in vivo model systems used to understand pathomechanisms in FTD, with a focus on disease models which reproduce aspects of the wide-ranging behavioural phenotypes seen in people with FTD. We discuss the emerging disease pathways that have emerged from these in vivo models and how this has shaped our understanding of disease mechanisms underpinning FTD. We also discuss the challenges of modelling the complex clinical symptoms shown by people with FTD, the confounding overlap with features of motor neuron disease, and the drive to make models more disease-relevant. In summary, in vivo models can replicate many pathological and behavioural aspects of clinical FTD, but robust and thorough investigations utilizing shared features and variability between disease models will improve the disease-relevance of findings and thus better inform therapeutic development.
Introduction
Frontotemporal dementia (FTD) is a group of clinically and pathologically variable neurodegenerative diseases with a common selective loss of neurons in the frontal and temporal cortices that leads to progressive changes in behaviour and language. When considering how to model the pathology and behaviour of FTD in rodents or other systems, we must first consider what aspects of the human disease we are trying to 'model'. This is usually behavioural and pathological features induced by the known causative genetic mutations. In the most common behavioural variant of FTD (bvFTD), patients exhibit loss of interpersonal and executive skills that is accompanied by emotional blunting and the appearance of unusual behaviours such as social withdrawal, confrontation seeking and personality changes. The less common language variants primarily present with a deterioration in language output, difficulty understanding the meaning of words, or hesitant speech and repetition. People with FTD also often develop motor symptoms. Indeed, symptoms resembling amyotrophic lateral sclerosis (ALS) are reported in up to half of FTD cases and the two diseases are considered to lie on a clinical continuum [1] [2] [3] . Pathologically, post mortem brains of people who had FTD are characterized with frontotemporal lobar degeneration (FTLD) and the presence of proteinaceous inclusions. The major protein deposited in these abnormal intracellular depositions is the RNA-binding protein TDP-43 (~50%), followed by the microtubule-associated protein tau (~40%) and rarer cases with another RNA-binding protein (FUS, 5%) or which have ubiquitinated inclusions but do not contain any of the above proteins. Around a third of FTD cases have a known genetic cause [4] . Of these, a third carry a repeat expansion mutation in the chromosome 9 open reading frame 72 (C9orf72) gene, followed by mutations in the genes for progranulin (GRN, 20%) and tau (MAPT,~10%). Other rare mutations include VCP, CHMP2B, UBQLN2 and SQSTM1. It is interesting to note that despite the strong pathological connection with TDP-43 and FUS, mutations in the genes that encoding these proteins are very rare in 'pure' FTD [5] [6] [7] [8] and FTD-ALS [7,9,10], and more frequently associated with ALS [11, 12] .
Challenges in modelling FTD
Modelling FTD in vivo is challenging on several levels. As described above, the disease is a heterogeneous disorder, with multiple phenotypic and pathological presentations and causative genetics. Although some correlations have been identified between genetics, pathology and clinical presentation, these are very overlapping and no one-to-one relationships occur [13, 14] . FTD also presents unique challenges for behavioural modelling, even in more complex model organisms such as the rodent. While there are a number of well-established tests designed to assess classic rodent cognitive function (e.g. the Morris water maze, novel object recognition, inhibitory avoidance and spontaneous alternation in the Y maze), the early changes in FTD patients do not fall into the category of classical memory loss. However, there are rodent tests that can be utilized to assess aspects of social behaviour that might reflect changes seen in behavioural variant FTD, such as social interaction and home cage behaviours. Language, as a uniquely human property, is more challenging to model, and while studies have demonstrated alterations in ultrasonic vocalizations in a tau mouse model of FTD [15] , these animals also demonstrate upper airway dysfunction that could impact on their ability to vocalize, hence further validation of the relevance of such tests in FTD models is required. These vocalization changes, however, cannot be used to model semantic deficits, or other more complex aspects of language that are affected in FTD, thus restricting the use of in vivo modelling for the language variants of FTD. In addition to its heterogeneous nature, FTD overlaps with ALS, and many aspects of FTD modelling are confounded by the presence of ALS-like pathology and motor phenotypes. This review will only focus on models where FTD-related phenotypes have been observed and not those which only display motor dysfunction in order to disentangle this issue.
Genetic models of FTD

Progranulin
Progranulin is a secreted glycoprotein which can be cleaved by proteases producing small peptides known as granulins, which both have roles in lysosomal function, neurite growth, synaptic transmission and neuroinflammation [16] . Several FTD-causing mutations in the progranulin gene (GRN) have been identified, which in nearly all cases present with TDP-43 pathology. The majority of mutations is frameshift and nonsense mutations that lead to premature stop codons in GRN and a reduction in progranulin protein expression [17] [18] [19] . Whereas people with FTD are heterozygous for GRN mutations, homozygous loss of GRN leads to a childhood-onset group of neurodegenerative diseases called neuronal ceroid lipofuscinosis (NCL), which generally include a combination of vision loss, epilepsy and cognitive decline [20] .
As GRN mutations result in haploinsufficiency, most studies modelling progranulin dysfunction either completely knockout or reduce the levels of the protein in order to model loss-of-function. Numerous mouse models with deletions in the mouse homologue Grn have been generated [16] . Behaviourally, homozygous knockout mice present with FTD-like phenotypes including impaired spatial learning and memory reduced the social recognition and interaction and compulsive behaviours [21] [22] [23] [24] [25] [26] . Heterozygous Grn knockout mice also present with milder social deficits, but still include reduced sociability [24, 27] . Homozygous knockout mice also show marked gliosis and inflammatory markers in the brain, and interfering with inflammatory pathways rescues several behavioural impairments and improves survival in these mice [28, 29] . Depending on the extent of knockdown (and potentially other factors), selective knockdown of progranulin in microglia is also sufficient to induce social grooming impairments and compulsive behaviour in mice [29, 30] . However, behavioural abnormalities in heterozygous Grn knockout mice and neuronal-specific knockout occur without concomitant microgliosis or neuroinflammation [24, 27] , suggesting that they are not essential for the development of these phenotypes. Compulsive behaviour is also present upon knockin of the most common mutation, R493X [31] .
Pathologically, development of TDP-43 pathology is mild with an increase in cytosolic phosphorylated TDP-43 in two homozygous knockout line and cytoplasmic mislocalization in homozygous R493X knockin mice [31, 34, 41] . Interaction between progranulin and TDP-43 has also been revealed in other models. Overexpression of human progranulin can rescue toxicity from overexpression of TDP-43 mutants in zebrafish [35, 36] and heterozygous loss of progranulin enhances toxicity from TDP-43 overexpression in worms [37] , indicating that haploinsufficiency of progranulin may render neurons susceptible to TDP-43 toxicity. As in humans, Grn knockout mice display gene-dosage dependent lysosomal pathology, with upregulation of lysosomal proteins and an increase in the number of lysosomes in both heterozygous and homozygous mice [27, 28, [31] [32] [33] [38] [39] [40] . Perhaps unsurprisingly homozygous knockout mice also present accumulation of lipofuscin, as found in the homozygous disorder NCL [23, 41] . The R493X knockin mice also display lipofuscin accumulation [31] , suggested that the mutation causes similar effects to loss of protein. Targeted viral expression of progranulin in neurons could improve lysosomal function and reverse social behaviour deficits in heterozygous knockout mice [27] . This suggests that lysosomal function and social behaviour are correlated but interference in the lysosomal pathway will be required to show causation.
These studies collectively imply that reduced progranulin can lead to FTD-like phenotypes in mice, with contributing roles of neurons, microglia and lysosomal dysfunction. Modelling progranulin-deficiency in mice also replicates the gene-dose consequences seen in human disease and may inform the contribution of different pathways to FTD or neuronal ceroid lipofuscinosis. Overall, the evidence for a contribution of progranulin loss-of-function for both diseases is strong and elevating progranulin levels may provide an effective therapy.
C9orf72
The C9orf72 protein is a guanine nucleotide exchange factor involved in the regulation of vesicular transport, particularly in the endolysosomal system and autophagy [42] . The C9orf72 mutation associated with FTD is a large expansion of an intronic hexanucleotide (GGGGCC) repeat upstream of the coding region [43, 44] . Three non-mutually exclusive hypotheses may explain how the C9orf72 mutation can cause pathogenesis: loss of C9orf72 protein and toxicity directly from expanded repeat RNA or the five different dipeptide repeat proteins (DPRs) produced by repeat-associated non-ATG-dependent translation (reviewed by [45] ). Pathologically, C9orf72-FTD brains exhibit RNA foci and inclusions of TDP-43 and all of the DPRs [46] [47] [48] [49] [50] [51] [52] . Models have been generated to assess each of these hypotheses.
Knockout or knockdown in Caenorhabditis elegans or zebrafish of C9orf72 orthologues leads to motor phenotypes [53] [54] [55] and knockout models in mice show no signs of neurodegeneration but primarily exhibit immune system abnormalities [56] [57] [58] [59] [60] [61] [62] [63] . One knockout mouse model does however display mild FTD-like phenotypes, including social interaction and recognition defects at 12 months of age [61] . Although genetic evidence does not suggest a predominantly loss-of-function mechanism in C9orf72-linked disease, these data support a potential contributing role to motor or sociability phenotypes, but further study in independent models is required to confirm this.
Expression of the expanded repeat without the rest of the C9orf72 gene is used to selectively model gain-offunction mechanisms. Expression of the repeat has the potential to produce both repeat RNA and DPRs, although does so to varying extents in different systems. Overexpression of the hexanucleotide GGGGCC repeat leads to neurodegeneration in C. elegans, Drosophila and zebrafish [64] [65] [66] [67] [68] [69] [70] [71] . To date, six mouse models carrying the pure repeat expansion exist and display variable phenotypes and pathology (reviewed by [72] [73] [74] ). Overexpression of 66 or 102 hexanucleotide repeats using intracerebral adenovirus injection to neonatal mice induces motor deficits with concomitant reduced social interaction and increased anxiety or cognitive decline respectively [75, 76] . Mouse models incorporating a mutant human C9orf72 gene and its endogenous promoter (using bacterial artificial chromosomes) display very different phenotypes: two show no behavioural or motor abnormalities [77, 78] , another exhibits learning and memory defects and increased anxiety without any motor impairment [61] , and another set primarily develop motor phenotypes prior to anxiety-like behaviour [79] . These models all exhibit RNA foci and variable sense DPR pathology, but no clear pathology-phenotype correlations are apparent in the models, nor with repeat length, making it difficult to dissect their roles in toxicity. However, mild TDP-43 pathology was present in models with behavioural phenotypes, although this was mostly nuclear rather than cytoplasmic as in disease.
Although it is generally agreed that gain-of-function is the dominant pathomechanism in C9orf72-linked FTD/ ALS, there is still much debate in the field as to which is the toxic gain-of-function species responsible for neurodegeneration. From in vivo models, there is evidence for both RNA and different DPR protein toxicity. RNA toxicity is primarily identified in systems where the expression of repeats occurs without detectable levels of DPRs, causing toxicity in chick spinal cord and motor axonopathy in zebrafish [80, 81] . Overexpression of puralpha which can bind to the repeat RNA rescues toxicity in zebrafish, strengthening a role for RNA toxicity [68, 81] . However, in Drosophila models expressing GGGGCC repeats interspersed with stop codons, to allow expression of RNA without translation into DPRs, no neurotoxicity or shortened lifespans is observed [67, 82] .
To investigate DPR-only toxicity, models have been generated where individual DPRs are expressed. When overexpressed, polypeptides of the arginine-rich DPRs glycine-arginine (GR) and proline-arginine (PR) have the greatest potential to induce neurotoxicity in Drosophila, C. elegans and zebrafish [66, 67, 80, 81, [83] [84] [85] [86] [87] [88] , but polypeptides of glycine-alanine (GA) also cause toxicity in Drosophila, zebrafish, chick embryo and mouse models [67, 80, [89] [90] [91] [92] [93] .The expression of 50 or 69 GA repeats via adenovirus-mediated delivery into neonatal mouse brain or zygote injection for (mostly) neuronal expression of 149 GA repeats induce development of primarily motor phenotypes [92] [93] [94] . However, memory deficits and increased anxiety were also identified in the (GA) 50 model [93] . In this model, all phenotypes were dependent on aggregation of GA polypeptides, which sequestered proteins involved in DNA repair, proteasomal targeting, and nucleocytoplasmic transport. GA expression resulted in a small increase in insoluble phosphorylated TDP-43 in one study [92] , and rare inclusions in another [93] . The expression of GFP-(GR) 100 using adenovirus-mediated delivery into neonatal mouse brain results in motor deficits and a progressive reduction in associative memory, associated with rare TDP-43 but no poly(GR) inclusions [95] . Surprisingly, although there is evidence for the association of poly(GR) with nucleolar stress, nucleocytoplasmic transport dysfunction and nuclear membrane integrity in cell models and patient tissue [86, [96] [97] [98] [99] , no evidence for these pathways was observed in this study. However, in Drosophila, expression of both (GR) 64 and (GA) 64 could cause the mislocalization of its homologues of TDP-43 and karyopherins 2 and 4 [100] .
Interestingly, models of individual toxic RNA-only or DPR entities do not recapitulate all the FTD-related behaviour seen in mice expressing the full C9orf72 mutation, which may indicate that a combination of entities is required to fully initiate FTD. However, the fact that expression of both poly(GA) and poly(GR) can both on their own result in abnormal TDP-43, albeit mildly, suggests that they can feed into the same pathological pathways. Indeed, in all models, behavioural phenotypes begin with the emergence of TDP-43 dysfunction in mice but do not require overt pathology. The development of models in which RAN translation of the C9orf72 repeat into DPRs can be turned on and off would provide further insight into relative contributions to disease initiation and maintenance. Such work requires a better understanding about the mechanisms of RAN translation and how it initiates, which is ongoing [101] .
CHMP2B
Mutations in CHMP2B are a rare cause of FTD, predominantly occurring in a large Danish family [102, 103] . Charged multivesicular body protein 2B (CHMP2B) is a subunit of the multi-protein ESCRT-III complex (endosomal sorting complex required for transport-III), which mediates membrane budding and fission. All mutations lead to C-terminal truncation of the CHMP2B protein, with loss of the Vps4-binding domain that is required for membrane scission, and loss of the autoinhibitory domain leading to excessive membrane protrusion [104] . In vivo studies show that overexpression of the predominant CHMP2B truncation CHMP2B Intron5 results in neurodegeneration, which is not observed when CHMP2B wildtype is overexpressed or knocked out [105, 106] . This suggests that CHMP2B mutations predominantly cause disease through a toxic gain-of-function. Work in Drosophila has demonstrated that the CHMP2B Intron5 mutant disrupts endosomal and autophagic trafficking resulting in synaptic overgrowth [107] . Behaviourally, CHMP2B Intron5 transgenic mouse lines all exhibit social interaction deficits, but display variable motor dysfunction; reduced anxiety and compulsive behaviours are seen in two of the three models, but no cognitive dysfunctions are apparent [106, 108, 109] . The different neuronal promoters may explain these differences and could be exploited to dissect the neuronal populations or spatiotemporal expression required for individual behavioural features. Pathologically, the behaviours are all associated with gliosis, axonopathy, the formation of TDP-43-negative, p62-positive inclusions and neurodegeneration -recapitulating the pathology seen in patient brains [105, [108] [109] [110] . CHMP2B Intron5 mice also develop a progressive lysosomal storage pathology, typified by autofluorescent aggregates in neurons and microglia, which are also found in patient brains [109] . Interestingly, these mice demonstrate microglial activation prior to neuronal loss and behavioural deficits [109] . As described above, lysosomal storage pathology and abnormal microglial activation are also widely reported in progranulin mouse models, suggesting that neuroinflammation and defective lysosomal degradation are common pathways underlying neurodegeneration in FTD, although the resultant inclusion pathology is different.
VCP
Mutations in the valosin-containing protein gene (VCP) were initially discovered to be causative for inclusion body myopathy with Paget disease of the bone and frontotemporal dementia (IBMPFD) [111] ; around a third of these cases present with FTD [112] . VCP mutations can cause variable syndromes within this spectrum and have been shown to also occur in ALS [113] . VCP is an AAA-type ATPase involved in many cellular processes, playing a central role in the ubiquitin protease system where it binds to ubiquitinated proteins targeting them for degradation by the proteasome [114] . Mutations primarily occur in the N-terminal region and do not result in reduced protein production, but rather interfere with protein-protein interactions. Human and mouse VCP are highly conserved only differing by a single residue enabling accurate knock in of disease-causing mutations into the endogenous mouse gene. Transgenic mice and knock in mice have been created for the most frequently occurring R155H mutation; the majority of behavioural tests in these mice have focused on motor phenotypes rather than FTD-relevant behaviours with mutant mice showing muscle weakness and impaired motor function [115] [116] [117] [118] [119] . Only transgenic expression of VCP containing mutations has been shown to induce FTD-like phenotypes. Global overexpression of VCP with either the R155H or A232E mutation exhibits increased anxiety and impaired novel object recognition in aged mutant mice [120] . Another model in which the VCP A232E mutation is overexpressed specifically in the forebrain also shows cognitive deficits including impaired spatial memory, object recognition and fear conditioning [121] .
As in people with VCP-associated FTD, a common feature of the above mutant VCP mice is an increase in protein ubiquitination and the presence of TDP-43 pathology, suggesting that compromised protein degradation is a consequence of VCP mutations in line with its known function in proteostasis. Indeed, VCP knockdown in zebrafish disrupts both proteasomal-and autophagy-mediated protein degradation [122] . In the murine models TDP-43 accumulates in the cytosol in VCP-negative aggregates; in one model TDP-43 inclusions also contained the stress granule marker TIA-1 additionally implicating stress granule dynamics in VCP-mediated TDP-43 mislocalization [121] . Overexpression of mutant VCP in Drosophila also causes accumulation of transgenic human TDP-43 in the cytoplasm [123] . Furthermore, the overexpression of the Drosophila homologue of VCP (ter94) supresses degenerative phenotypes caused by knockdown of endogenous Drosophila TDP-43 (TBPH), whereas loss of ter94 enhances toxicity [124] . These data suggest physiological VCP function maintains TDP-43 distribution, providing neuroprotection against TDP-43 related toxicity. Mitochondrial defects are also observed in VCP mutant mice [117, 118, 120] , though this has not been investigated in the models exhibiting FTD-like phenotypes. However, this has been recapitulated in Drosophila where VCP mutants promote mitofusin degradation leading to disrupted fission of mitochondria [125] . Overall, these models suggest VCP mutations not only disrupt the ubiquitin protease system, but also autophagy and mitophagy pathways.
Ubiquilin 2
Missense mutations in the gene encoding ubiquilin 2 (UBQLN2) are a rare cause of FTD and ALS [126] [127] [128] . Ubiquilin 2 is an adaptor protein that shuttles between the nucleus and the cytoplasm and is thought to play roles in both delivering ubiquitinated proteins to the proteasome for degradation and autophagy [129] . UBQLN2 mutations predominantly affect the central proline-rich segment which mediates proteinprotein interactions and self-association of ubiquilin 2. UBQLN2 mutations lead to cytoplasmic inclusion pathology in brain and spinal cord, which is also present in non-UBQLN2 ALS and FTD cases [126, 130] .
Knockdown of the single ubiquilin homologue in Drosophila (similar to mammalian ubiquilins 1 and 2) leads to widespread changes in synaptic morphology, resulting in defective locomotion and learning, assessed by Pavlovian odour-reward learning [131] . However, knockdown only of endogenous UBQLN2 in rats produces no learning and memory phenotypes [132] , indicating that mutations in UBQLN2 may exert their effects primarily via a toxic gain-of-function. Mice or rats transgenically expressing UBQLN2 P497H with the neuronal CaMKII or the human UBQLN2 promoter develop cognitive dysfunction [132, 133] , which is also apparent in UBQLN2 P506T knockin mice [134] . In mice overexpressing UBQLN2 P497H under the human UBQLN2 promoter, deficits in temporal and spatial memory are associated with abnormal dendritic spines and impaired synaptic transmission [133, 135] . Mice transgenic for the UBQLN2 mutations P497S and P506T uniquely develop motor abnormalities in addition to cognitive impairment with expression is driven from the pan-neuronal Thy1.2 promoter [136] . Learning and memory deficits are also reported in Drosophila expressing mutant variants of UBQLN2 [137] . Although in mouse models, the overexpression of wildtype UBQLN2 does not induce disease-associated phenotypes or reduced survival [136, 138] ; in rats, it is sufficient to cause neurodegeneration and impaired cognition [139] .
Inclusions of ubiquilin 2 were frequent in all murine models, including those overexpressing wildtype protein, though much less frequent than with the mutants [132] [133] [134] 136, 138, 139] . Ubiquilin 2 inclusions are also positive for proteasome subunits and the autophagosome marker LC3-II [133, 139] . Indeed, a common feature to all UBQLN2 models is impairment in the ubiquitin proteasome system, showing an overall increase in ubiquitinated proteins [133, 134, 139] . In Drosophila expression of both wildtype and disease-associated UBQLN2 mutations also perturbs ubiquitin homeostasis leading to toxicity, which can be prevented by mutations that prohibit ubiquitin binding [137] . Interestingly, TDP-43 co-aggregated with ubiquilin 2 in UBQLN2 mutant transgenic mice but was not associated with cognitive phenotypes [136, 138] , similar to their pathological association in people with ALS/FTD [126] . Thus UBQLN2 models support the growing evidence that impaired protein degradation is a common pathogenic mechanism in FTD. p62 p62 (also known as sequestome-1) is another multifunctional protein that targets specific cargoes for autophagy [140] . Mutations in the gene encoding p62 (SQSTM1) are a rare cause of FTD and are enriched in the ubiquitin-binding domain [141] . These carriers display variable TDP-43 pathology in cortical and hippocampal regions and white matter [141] . As with VCP, mutations in SQSTM1 also cause Paget's disease of bone [142] and ALS [143] . Knockdown of the zebrafish homologue of p62, sqstm1, results in axonal deficits and defective motor behaviour, which could be rescued by enhancing autophagy [144] . Sqstm1 knockout mice show several FTD-like phenotypes including impaired working memory, anxiety and depression, amongst other metabolism-related phenotypes, whilst motor function was preserved [145] . Surprisingly, these mice display tau pathology, although SQSTM1 mutations are associated with FTLD-TDP-43 [141] . Conversely, transgenic overexpression of p62 in the hippocampus of mice leads to enhanced mitochondrial functionality, which correlates with improvements in spatial long-term memory formation and an increase or decrease in anxiety (depending on the test) and activity compared to wildtype mice [146] . Overexpression of an FTD-related mutant form of p62 which prevents binding to ubiquitin shows no overall change in ATP production, with decreased anxiety, changes in activity, but no improvement in long-term memory, different to the wildtype protein [146] . Although interesting, clearly further work and models with physiological levels of mutant protein (such as a knockin) are required to clarify the contribution of loss-or gain-offunction mechanisms in SQSTM1-associated FTD.
Modelling FTD pathology directly
FTLD-TDP-43
TAR DNA binding protein of 43 kDa (TDP-43) is an evolutionary conserved multifunctional RNA-binding protein predominantly localized to the nucleus [147] . TDP-43 is the main component of cytoplasmic inclusions found in the most common pathological form of FTLD [148] . Mutations in the TDP-43 gene (TARDBP) are very rare in FTD, but still indicate a primary mechanistic role for TDP-43 in disease. In FTLD-TDP-43, ubiquitinated and hyperphosphorylated TDP-43 inclusions are associated with loss of protein from the nucleus [148, 149] . Loss of TDP-43 from the nucleus suggests a loss-of-function as a central pathogenic mechanism, whilst the presence of cytoplasmic TDP-43 aggregates may suggest a toxic gain-of-function; indeed, functional studies in animal models support both possibilities.
Complete TDP-43 knockout in mice is lethal both embryonically and rapidly upon post-natal induction [150] [151] [152] . Heterozygous knockout allows mice to reach maturity, but results in motor deficits in aged animals [152] . Partial knockdown of the Drosophila orthologue of TDP-43 (TBPH) causes deficits in synaptic transmission [153, 154] and impaired steroid signalling [155] . TDP-43 gain-of-function studies have employed overexpression of either wildtype or mutant TDP-43, both of which cause toxicity in C. elegans [156] , Drosophila [157] , zebrafish [158] and rodent [94, [159] [160] [161] [162] [163] [164] [165] [166] [167] [168] [169] [170] [171] . As TDP-43 pathology also accounts for the vast majority of ALS cases, most studies modelling TDP-43 dysfunction have focused on ALS-associated motor phenotypes. However, utilization of the CamKII promoter to produce dominant overexpression in the forebrain has been used to explore FTD pathomechanisms. Transgenic CaMKII-TDP-43 wildtype or mutant mice (lacking the nuclear localization signal) present with significant early wide-ranging cognitive impairments and disrupted social interaction in addition to motor phenotypes [159, 168, 172] . Interestingly, when transgene expression was switched off in the TDP mutant mice cognitive and motor deficits could be rapidly reversed in young mice while social dysfunction persisted, suggesting variable reversibility of pathology in different neuronal systems [172] .
One very important finding from mouse models of TDP-43 dysfunction is that neither cytoplasmic aggregation of TDP-43 nor complete loss from the nucleus is required for neurotoxicity [160, 168, 171, 173, 174] , indicating that TDP-43 aggregation and mislocalization may only occur in latter stages of disease. This is in line with other genetic models where overt TDP-43 pathology was often not present upon appearance of behavioural phenotypes. Toxicity can however correlate with the level of TDP-43 expression; high-mutant transgene expression during development causes neurodegeneration and impaired survival without the presence of TDP-43 aggregates, whereas lower expression does not [173] . That both TDP-43 loss and overexpression are highly toxic indicates that physiological TDP-43 levels must be tightly controlled. Indeed, TDP-43 can negatively regulate the expression of its own RNA levels by binding to its 3 0 untranslated region and stimulating RNA degradation [175] . The importance of TDP-43 autoregulation has been highlighted in a recent model in which the ALS Q331K point mutation was knocked in to the equivalent residue in the endogenous mouse Tardbp gene [176] . Intriguingly, these TDP-43 Q331K knockin mice display only late-stage motor impairment but present with cognitive impairment reminiscent of FTD, including executive dysfunction, hyperphagia and impaired memory. This cognitive dysfunction was associated with perturbed TDP-43 autoregulation as evidenced by intron 7 retention and an increase in RNA and nuclear protein levels. Transcriptomic analysis of these mice also revealed other differentially regulated genes including inclusion of exons 2 and 3 of the Mapt gene encoding tau, providing the first mechanistic link between these two major pathological hallmarks of FTD. This suggests that TDP-43 gain-of-function may be crucial to the initial stages of disease, as behavioural phenotypes and splicing alterations occurred without accompanying TDP-43 aggregation and nuclear clearance. Gain-offunction splicing changes are seen in another TDP-43 knockin mouse model also with a mutation in the Cterminus, although this is associated with a motor phenotype [174] . Thus, in in vivo it appears that gain-offunction has more potential to cause FTD (and ALS) than loss-of-function.
FTLD-FUS
Following the identification of mutations in the gene encoding the RNA-binding protein FUS as causative for rare forms of ALS [12, 177] , the inclusions in a subset of atypical (non-TDP-43) FTLD were shown to contain aggregated FUS [178] . The other members of the FET family, TAF15 and EWS, can also be found in these inclusions, and strikingly their nuclear import receptor transportin-1; the presence of these additional proteins and hypomethylation of FUS distinguishes FTLD-FUS from ALS-linked FUS only pathology [179] [180] [181] [182] . Like TDP-43, FUS and the other FET proteins are RNA-binding proteins with a predominant function in RNA metabolism and transport [183] . Three very rare cases of FTD with FUS mutation (one FTD, two FTD-ALS) have been reported [8-10]. Knockdown of FUS leads to contrasting phenotypes across and within species. Zebrafish FUS CRISPR knockouts show no phenotype and are viable and healthy [184] . In mice, homozygous FUS knockout causes postnatal lethality, but heterozygous mice are indistinguishable from wildtypes [185, 186] . Interestingly homozygous knockout FUS mice on an outbred line could survive to adulthood, but display cognitive phenotypes including a reduction in anxiety-like behaviour and hyperactivity [185, 187] . When FUS is virally knocked down in the hippocampus similar reductions in anxiety are observed with concomitant social but not memory deficits [188] . These changes were associated with reduced hippocampal neurogenesis and could be rescued by normalizing the balance in tau isoforms [189] , adding more evidence to shared pathomechanisms in FTD. The only study of the other FET proteins is a knockout EWS mouse model which shows early post-natal lethality [190] similar to FUS. In the majority of Drosophila, zebrafish and rodent models, overexpression of FUS whether wildtype or containing ALS-linked mutation leads to motor phenotypes [162, [191] [192] [193] [194] [195] [196] [197] [198] [199] , also observed in knockin models [200] [201] [202] [203] , suggesting that this is the dominant phenotype in response to increased FUS. However, in some models, nonmotor phenotypes have been seen. In a rat model overexpressing wildtype FUS no motor symptoms were present, but in aged animals there were signs of neuronal loss in the cortex and dentate gyrus with a deficit in spatial learning and memory [199] . In a mouse model overexpressing FUS lacking its nuclear localization signal (and thus mislocalized to the cytoplasm) with the pan-neuronal Thy1.2 promoter, symptoms associated with FTD are seen prior to the onset of motor deficits; phenotypes included social interactional deficits and impaired fear memory retrieval, accompanied by changes in synaptic density in the frontal cortex [204, 205] . However, when FUS is expressed in mice using its endogenous promoter, mutants, but not wildtype, cause early motor phenotypes and late cognitive and social deficits; early motor symptoms were associated with reduced translation in axons [206] . In summary, FTD-related phenotypes have been identified in both gain-and loss-of-function FUS models in varying coincidence with motor phenotypes. With further study, these differences could be used to inform contribution of different pathways to FTD-or ALS-linked clinical symptoms.
Converging pathways implicated from FTD modelling
Although many pathways and mechanisms have been identified from the study of genetic and pathologic in vivo models of FTD, several convergent mechanisms are emerging (Figure 1) . Interestingly, genes which cause FTD alone or FTD/ALS encode proteins which have functions associated with protein degradation and a dysfunctional autophagy/lysosomal pathway, including C9orf72, VCP, SQSTM1, UBQLN2, CHMP2B and GRN. This suggests that FTD is associated with inhibited proteostasis, as previously proposed [207] . Indeed, in vivo studies reflect this; autolysosomal dysfunction is a common theme in GRN and CHMP2B models and has also been reported in models targeting VCP and C9orf72 [208, 209] . The main risk factor for FTD, TMEM106B, also functions in the endolysosomal pathway [210] [211] [212] .
A second major pathway exists based on the pathological proteins that accumulate in FTD, namely TDP-43 and FUS. These RNA-binding proteins' primary role is in RNA metabolism, which becomes dysfunctional in FTD. How cytoplasmic accumulation of TDP-43 and FUS initiates remains a key question, particularly as the majority of FTD (and ALS) cases are not caused by genetic mutation of the genes encoding these proteins. These proteins shuttle between the nucleus and the cytoplasm through the nuclear pore using the nucleocytoplasmic transport machinery. Proteins involved in this pathway, including both transport factors and proteins that comprise the nuclear pore complex, can even modify toxicity in C9orf72 models, as described above. Indeed, a multiple hit hypothesis for TDP-43 aggregation has been proposed in which the first hit is defective nuclear import, followed by cytoplasmic accumulation and aggregation of TDP-43, probably by chronic sequestration into stress granules and thus irreversible seeding of aggregation [213] . Nuclear transport is also highlighted by bioinformatic-interaction network analysis on genes implicated by genetics or pathology in FTD or ALS [214] . In addition, cytoplasmic aggregation of both disease-relevant and synthetic proteins in vitro can cause mislocalization of nucleocytoplasmic transport and nuclear pore proteins [215] . This suggests a role for nucleocytoplasmic transport in initiating and propagating disease within a cell.
Models of FTD also implicate other key biological pathways in disease, including mitochondrial dysfunction, inflammation (particularly microglia), RNA and protein transport, and the cytoskeleton (associated with FTLD-tau, not covered within this review). Implicated pathways may indicate particular vulnerability of the neurons that degenerate in FTD [216] or indeed between different FTD variants, as has been suggested in Alzheimer's disease [217] . Many other cellular pathways have been implicated in cellular models. Of particular interest may be the differences in the phase separation of proteins and the implications of this for Figure 1 . Converging cellular pathways implicated in FTD pathogenesis from in vivo models exhibiting disease-relevant behavioural phenotypes and the associated genes. Dysfunctional proteostasis is highlighted in almost all models, perhaps unsurprisingly, as mislocalization and aggregation of protein is a key feature of FTD and all neurodegenerative diseases. Even genes encoding proteins with different primary functions feed into converging pathways. The C9orf72 mutation is unique in its complexity due to the production of multiple novel and potentially toxic RNA and protein species, which can exert dysfunction in different and overlapping pathways. stress granule dynamics, which are proposed to be the precursor for pathological aggregates [218, 219] , particularly concerning TDP-43 and FUS which are recruited to stress granules during cellular stress. It is probable that no single mechanism or pathomechanism is responsible for the complex and variable behaviours seen in FTD, but more likely the result of the combined dysfunction of multiple toxic entities in multiple systems interacting to generate the cascade of neurodegeneration. Subtle differences in the systems and neurons affected may result in the variable clinical presentation, even from the same genetic mutation.
Conclusions and Future Perspectives
Modelling FTD by mutation of single genes associated by disease mutation or pathology results in variable phenotypes in C. elegans, Drosophila, zebrafish and rodents. In rodents, these include phenotypes and pathology reminiscent of behavioural variant FTD (Table S1, Figure 2 ). However, relating behavioural changes in rodents to clinical features is challenging and generally implied by assuming that similar networks control the same behaviours in mice and humans [220] . Phenotypes more specific to FTD are generally considered to be the presence of altered sociability and behavioural changes in anxiety and compulsivity. Reduced sociability of rodents is used to represent deficits in emotion processing or lack of empathy in FTD and is associated with most genetic models presented above. Interestingly, bidirectional changes in anxiety and activity are often described as FTD-related. Reduced anxiety is associated with disinhibition and reduced activity to apathy, whereas increases are related to more general erratic behaviour. Other noted phenotypes include compulsive or repetitive behaviours which do occur in FTD and manifest in rodents in behaviours such as grooming or overeating. Changes in cognition are widely reported, which is in part probably due to their common study in dementia models and is often used to show central nervous dysfunction outside the motor system. However, there is increasing evidence for memory impairments in FTD [221] , and therefore memory-type cognitive changes in models are potentially relevant. Motor symptoms are present in most models, which may be unsurprising considering that many of these genes are associated with ALS but may also reflect the high proportion of people with FTD who exhibit some form of motor dysfunction. Features of motor system dysfunction were notably absent in progranulin models, replicating their absence in FTD caused by GRN mutation. Conversely, models of tau-associated FTD (not covered within this review) do exhibit motor phenotypes in addition to behavioural and cognitive symptoms [220] although these are not typically found in FTD caused by mutation in MAPT.
An alternative way to study FTD pathomechanisms in vivo is by modelling pathology, as described above, which can inform shared cellular pathomechanisms downstream of genetic mutations and common to disease with no known cause. Pathology in models gives insight into dysregulation at the cellular level in an intact nervous system and can provide a link between in vitro studies and end stage human pathology. The presence of relevant behavioural phenotypes can then add another level of distinction to whether this dysfunction can affect the function of the neuronal networks that degenerate in FTD. Associating spatial and temporal patterns of pathology with a range of behavioural tests and cross-comparison of models will better inform specificity to particular features of this clinically variable disease, including relevance to FTD and/or ALS. In FTD/ALS genetic models this should particularly include the study of social and home cage behaviours, which are often overlooked for the more common motor and cognitive tests. This may also include newer behavioural assessment methods; it has recently been proposed that many FTD symptoms are due to dysfunction in goal-directed behaviours, which can be studied by action-outcome association tests in rodents [222] . Mouse background strain variation can also have a profound effect on various phenotypic outcomes [223] and may account for some of the observed differences in models. Harnessing this feature may provide insight into genetic influencers of diseaserelated behaviours. Expression profiling and stratification have already provided molecular insight within a FTD model exhibiting significant phenotypic variation [176] .
Due to the failure of clinical trials using treatments that show effect in murine models, there is a drive to make models more physiological and disease-relevant. Knocking in disease-causing mutations into the relative position in mouse genes and replacement of murine genes with human overcome artefacts from overexpression or complete knockout, and model both potential loss and gain-of-function. Ideally, these mice would be used to study age-dependent phenotypes in the heterozygous state, as generally found in human disease. There is often concern that these modifications will result in mild or no phenotypes resembling disease within the murine lifespan; however, several of these models have now shown significant behavioural changes, often resembling previous models. However, even humanized models still have the caveat that the molecular environment into which the human proteins are investigated remains murine, and it is difficult to assess the impact of this. The use of patient-derived stem cells overcomes this issue, although when differentiated into neurons, these cells are highly variable, remain immature and are therefore limited to model early and overt molecular changes. Comparisons to clinical and post mortem studies for confirmation of downstream consequences of impairment in identified molecular pathways remain essential, but these lack resolution and the time-course of changes. Thus, there is no perfect model. Overexpression or knockout models are still crucial as a first step to identify potential neurotoxicity and exploring pathomechanisms, but when considering the translational potential of these findings, validation in more disease-relevant models will better inform disease contribution. Indeed, as the minority of FTD cases has a known genetic cause, comparisons between and even combination of models of single genes may identify more robust therapeutic targets for disease. Figure 2 . FTD-relevant behavioural phenotypes in murine models and the associated genes. Some form of impaired cognition and motor phenotypes are identified in most models and are frequently investigated due to the association of genes with dementia (including FTD) and the motor neuron disease amyotrophic lateral sclerosis (ALS), respectively. Behavioural changes are detected in tests predicting anxiety, depression and hyperexcitability and are proposed to represent apathy or erratic behaviour in FTD; other phenotypes in this category include compulsive behaviours, such as excessive self-grooming. In-depth investigation of social behaviour is less common but still notable in the majority of models. Defective communication has only been implicated from alterations in vocalization in one model overexpressing mutant tau (encoded by MAPT), although caveated by concurrent dysfunction in upper airways. 
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